诺和诺德在研减肥药公布新数据!礼来替尔泊肽快速逼近,新一轮竞争如何应对?

医药经济报
21 Feb

数百亿美元超级重磅GLP-1减重赛道竞争白热化!诺和诺德在研药物Amycretin最新临床试验数据,引发行业震动。前不久,诺和诺德(Novo Nordisk)公布了在研药物Amycretin 的1b/2a期临床试验的顶线结果。据悉,本次数据涉及的Amycretin是一种单分子胰高血糖素样肽-1(GLP-1)和胰淀素受体激动剂,每周进行一次皮下注射。事实上,虽然司美格鲁肽已经取得了逼近“全球药王”的...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10